📊 EDSA Key Takeaways
Is Edesa Biotech, Inc. (EDSA) a Good Investment?
Pre-revenue biotech company burning $4.1M annually with deteriorating fundamentals (-16.5% YoY net income decline). While the balance sheet is strong with $10M cash and zero debt, current burn rate implies only 2.4 years of runway without revenue generation or capital raises, creating significant execution risk. Lacks clear near-term catalysts or revenue inflection points to justify continued cash depletion.
Edesa Biotech remains a pre-revenue company with ongoing operating losses and negative free cash flow, so the core fundamental profile is still weak. Its balance sheet is a clear offset, with substantial cash, very high liquidity, and no meaningful debt, which supports near-term funding flexibility. Overall, the company appears financially stable in the short run but lacks demonstrated revenue generation or durable profitability trends.
Edesa Biotech, Inc. Key Strengths (EDSA)
- Minimal leverage with zero long-term debt and 0.00x debt-to-equity ratio
- Strong liquidity position (4.76x current ratio, 4.73x quick ratio) providing operational runway
- Substantial cash reserves of $10.0M reducing near-term solvency risk
- Strong liquidity with $12.10M in cash and current ratio of 16.82x
- Debt-free balance sheet with low liabilities relative to equity
- Net loss improved year over year, indicating some expense discipline
EDSA Stock Risks: Edesa Biotech, Inc. Investment Risks
- Zero revenue with no evidence of commercial progress or product launches
- Negative operating cash flow of -$4.1M annually with depleting cash runway
- Worsening profitability trend with net income declining 16.5% YoY despite cost structure
- High biotech development risk: clinical trial failures, regulatory rejection, and potential dilutive capital raises
- Current cash position suggests 24-30 months runway at existing burn rate if no revenue materializes
- No revenue generation, making the business dependent on external financing or existing cash reserves
- Continued negative operating cash flow and free cash flow indicate ongoing cash burn
- Weak growth quality due to the absence of commercial traction and recurring losses
Key Metrics to Watch
- Operating cash flow trend and monthly burn rate
- Clinical trial progress and FDA regulatory milestones
- Quarter-over-quarter cash depletion rate and runway extension plans
- Revenue inflection or partnership/licensing deal announcements
- Capital raise activities and potential shareholder dilution
- Quarterly cash burn versus cash balance
- Progress toward revenue generation or commercialization milestones
Edesa Biotech, Inc. (EDSA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.76x current ratio provides a solid financial cushion.
EDSA Profit Margin, ROE & Profitability Analysis
EDSA vs Healthcare Sector: How Edesa Biotech, Inc. Compares
How Edesa Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Edesa Biotech, Inc. Stock Overvalued? EDSA Valuation Analysis 2026
Based on fundamental analysis, Edesa Biotech, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Edesa Biotech, Inc. Balance Sheet: EDSA Debt, Cash & Liquidity
EDSA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Edesa Biotech, Inc.'s revenue has declined by 74% over the 5-year period, indicating business contraction. The most recent EPS of $-1.93 indicates the company is currently unprofitable.
EDSA Revenue Growth, EPS Growth & YoY Performance
EDSA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$1.7M | N/A |
| Q2 2021 | N/A | -$1.5M | N/A |
| Q1 2021 | N/A | -$1.1M | N/A |
| Q3 2020 | $500 | -$1.3M | N/A |
| Q2 2020 | N/A | -$455.6K | N/A |
| Q1 2020 | N/A | -$347.1K | N/A |
| Q2 2019 | N/A | -$392.3K | N/A |
| Q1 2019 | $20.5K | -$1.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Edesa Biotech, Inc. Dividends, Buybacks & Capital Allocation
EDSA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Edesa Biotech, Inc. (CIK: 0001540159)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EDSA
What is the AI rating for EDSA?
Edesa Biotech, Inc. (EDSA) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EDSA's key strengths?
Claude: Minimal leverage with zero long-term debt and 0.00x debt-to-equity ratio. Strong liquidity position (4.76x current ratio, 4.73x quick ratio) providing operational runway. ChatGPT: Strong liquidity with $12.10M in cash and current ratio of 16.82x. Debt-free balance sheet with low liabilities relative to equity.
What are the risks of investing in EDSA?
Claude: Zero revenue with no evidence of commercial progress or product launches. Negative operating cash flow of -$4.1M annually with depleting cash runway. ChatGPT: No revenue generation, making the business dependent on external financing or existing cash reserves. Continued negative operating cash flow and free cash flow indicate ongoing cash burn.
What is EDSA's revenue and growth?
Edesa Biotech, Inc. reported revenue of $0.0.
Does EDSA pay dividends?
Edesa Biotech, Inc. does not currently pay dividends.
Where can I find EDSA SEC filings?
Official SEC filings for Edesa Biotech, Inc. (CIK: 0001540159) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EDSA's EPS?
Edesa Biotech, Inc. has a diluted EPS of $-0.57.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is EDSA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Edesa Biotech, Inc. has a C grade with 77% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is EDSA stock overvalued or undervalued?
Valuation metrics for EDSA: ROE of -63.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is EDSA's AI grade for 2026?
Our dual AI analysis gives Edesa Biotech, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EDSA's free cash flow?
Edesa Biotech, Inc.'s operating cash flow is $-4.1M, with capital expenditures of $0.0.
How does EDSA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -63.4% (avg: 15%), current ratio 4.76 (avg: 2).